Membranous nephropathy associated with oxaprozin treatment.
Ogawa
M
M
Ueda
S
S
Hamano
Y
Y
Ito
K
K
Saisho
H
H
Akikusa
B
B
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D001416:Back Pain / Q000188:drug therapy*; D002196:Capillaries / Q000473:pathology / Q000648:ultrastructure; D003176:Complement C3 / Q000032:analysis; D004487:Edema / Q000139:chemically induced* / Q000473:pathology; D004848:Epithelium / Q000473:pathology / Q000648:ultrastructure; D015433:Glomerulonephritis, Membranous / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D007074:Immunoglobulin G / Q000032:analysis; D007678:Kidney Glomerulus / Q000098:blood supply / Q000473:pathology; D007866:Leg; D008297:Male; D009543:Nifedipine / Q000627:therapeutic use; D000077431:Oxaprozin; D011422:Propionates / Q000009:adverse effects*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D003176:Complement C3; D007074:Immunoglobulin G; D011422:Propionates; D009543:Nifedipine; D000077431:Oxaprozin